Short Interest in Portage Biotech Inc. (NASDAQ:PRTG) Increases By 1,628.6%

Portage Biotech Inc. (NASDAQ:PRTG) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 242,000 shares, an increase of 1,628.6% from the June 30th total of 14,000 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average daily volume of 911,300 shares, the short-interest ratio is presently 0.3 days.

Portage Biotech Stock Down 3.2 %

Shares of NASDAQ PRTG opened at $0.18 on Thursday. The stock has a fifty day simple moving average of $0.24 and a two-hundred day simple moving average of $0.46. Portage Biotech has a 1-year low of $0.13 and a 1-year high of $3.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.78 and a quick ratio of 2.78.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.